Haemonetics Corporation (HAE)

Market Cap	2.60B
Revenue (ttm)	1.35B
Net Income (ttm)	163.34M
Shares Out	48.18M
EPS (ttm)	3.28
PE Ratio	16.44
Forward PE	10.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,274,425
Open	52.25
Previous Close	52.23
Day's Range	51.83 - 54.06
52-Week Range	50.68 - 94.99
Beta	0.40
Analysts	Buy
Price Target	86.73 (+60.97%)
Earnings Date	Aug 7, 2025

About HAE

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools....

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,023
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In 2024, Haemonetics's revenue was $1.36 billion, an increase of 3.95% compared to the previous year's $1.31 billion. Earnings were $167.68 million, an increase of 42.64%.

Analyst Forecast

According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $86.73, which is an increase of 60.97% from the latest price.

Price Target

$86.73

(60.97% upside)

Analyst Consensus: Buy